Podcast appearances and mentions of Mario R Nacinovich

Host: Mario R. Nacinovich, Jr., MSc Guest: Randy Young, MD Amid the surge of the Delta variant, critical care physician Dr. Randy Young is traveling to ICUs across the country to help treat patients. Tune in to hear Dr. Young share how this surge is impacting both patients infected with the variant and the healthcare professionals caring for them.

Host: Mario R. Nacinovich, Jr., MSc Guest: Lyudmila Bazhenova, MD Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges. To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

Host: Mario R. Nacinovich, Jr., MSc Guest: Lyudmila Bazhenova, MD Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges. To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

Host: Mario R. Nacinovich, Jr., MSc Guest: Sara Tolaney MD, MPH Triple-negative breast cancer comprises up to 20 percent of all breast cancer diagnoses, and unfortunately, survival for these patients has been more limited than in other subtypes of disease. That’s why improving outcomes for patients with triple-negative breast cancer has been the focus of recent studies—much like the one investigating eribulin and pembrolizumab that Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute, presented at the 2020 ASCO Annual Meeting.

Host: Mario R. Nacinovich, Jr., MSc Guest: Sara Tolaney MD, MPH Triple-negative breast cancer comprises up to 20 percent of all breast cancer diagnoses, and unfortunately, survival for these patients has been more limited than in other subtypes of disease. That’s why improving outcomes for patients with triple-negative breast cancer has been the focus of recent studies—much like the one investigating eribulin and pembrolizumab that Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute, presented at the 2020 ASCO Annual Meeting.

Host: Mario R. Nacinovich, Jr., MSc Guest: Gregory J Kubicek, MD What treatments and technologies are on the horizon for our patients with non-small cell lung cancer? Joining Mario Nacinovich to give us a look at what’s ahead is Dr. Gregory Kubicek, staff radiation oncologist at the MD Anderson Cooper Cancer Center.

Host: Mario R. Nacinovich, Jr., MSc Guest: Gregory J Kubicek, MD What treatments and technologies are on the horizon for our patients with non-small cell lung cancer? Joining Mario Nacinovich to give us a look at what’s ahead is Dr. Gregory Kubicek, staff radiation oncologist at the MD Anderson Cooper Cancer Center.

Host: Mario R. Nacinovich, Jr., MSc Guest: David Fajgenbaum, MD Since its founding, the Castleman Disease Collaborative Network (CDCN) has worked to identify an effective treatment for Castleman disease, a rare immune system disorder that leads to a cytokine storm and multi-organ failure—much like what's being seen in COVID-19 patients. Here to review how the CDCN's innovations are now being leveraged toward the fight against COVID-19 is the CDCN's Co-Founder and Executive Director Dr. David Fajgenbaum.

Host: Mario R. Nacinovich, Jr., MSc Guest: Mark R. Cullen, MD Even before the COVID-19 pandemic hit, endemic challenges surrounded fragmented data sets and long perspective clinical trials. But now, recently developed data sets are available to public health and policy researchers to not only overcome that challenge, but also to combat this global pandemic. Dr. Mark Cullen, Scientific Committee Chair for the academic arm of the COVID-19 research database at Stanford University School of Medicine, joins Mario Nacinovich to explain. Published May 13, 2020

Host: Mario R. Nacinovich, Jr., MSc Guest: Randy Young, MD Here to give us a firsthand look into how ICUs across the country are confronting the COVID-19 pandemic head-on is Dr. Randy Young, a critical care doctor who's treating COVID-19 patients in the mid-Atlantic area. Dr. Young joins Mario Nacinovich to discuss what he has seen during the pandemic and how the ICU is responding to both expected and unexpected challenges. Published May 13, 2020

Host: Mario R. Nacinovich, Jr., MSc Guest: Salman Ahmed, MD, MPH During the COVID-19 pandemic, e-consults have become the new norm, but what impacts do they have on patient care? To find out, Mario Nacinovich is joined by Dr. Salman Ahmed, who takes us through his research finding that e-consults might not just be the appropriate choice, but the preferred one over face-to-face appointments. Published May 13, 2020

Host: Mario R. Nacinovich, Jr., MSc Guest: Renata Schiavo, PhD, MA COVID-19 is constantly referred to as a global pandemic, but how often do you think of it as an info-demic? Or as a health equity issue? Joining Mario Nacinovich to give us a look at COVID-19 through a different lens is Dr. Renata Schiavo, Senior Lecturer, Columbia University Mailman School of Public Health, Department of Sociomedical Sciences and Founder and President of the Board of Directors of the Health Equity Initiative. Dr. Schiavo discusses common barriers faced by the most vulnerable populations and how we can protect them during and after the COVID-19 pandemic. Published April 28, 2020

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Riess, MD, MS Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center.

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Riess, MD, MS Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center.

Host: Mario R. Nacinovich, Jr., MSc Guest: Michael R. Shafique, MD Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Host: Mario R. Nacinovich, Jr., MSc Guest: Michael R. Shafique, MD Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Host: Mario R. Nacinovich, Jr., MSc Guest: Anthony Dragun, MD Throughout this global pandemic, radiation oncologists are faced with the challenge of finding ways to continue administering the necessary cancer treatments while limiting their patients' risk of exposure to COVID-19. Dr. Anthony Dragun from the MD Anderson Cancer Center is here to explain how that can be done and why these new approaches should be embraced even after the COVID-19 pandemic is over. Published April 27, 2020

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Riess, MD, MS Due to the many challenges and complications that are now facing oncologists and their patients requiring lung cancer treatment, lung cancer care is changing in many ways to help minimize a patient's risk of exposure, as Dr. Jonathan Riess from the UC Davis Medical Center explains. Published April 24, 2020

Host: Mario R. Nacinovich, Jr., MSc Guest: Charles P. Gerba, MD The novel coronavirus outbreak that began in late 2019 may be the first global epidemic pronounced in the social media age, with myths and misinformation populating just as quickly and frequently as new cases. But is there any truth behind these claims? Here to shed light on this global health crisis is microbiologist Dr. Charles Gerba.

Host: Mario R. Nacinovich, Jr., MSc Guest: Paul Orchard, MD Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That’s why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it’s often underdiagnosed and confused with other conditions, and how we can treat it once we’ve reached an accurate diagnosis.

Host: Mario R. Nacinovich, Jr., MSc Guest: Paul Orchard, MD Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That’s why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it’s often underdiagnosed and confused with other conditions, and how we can treat it once we’ve reached an accurate diagnosis.

Host: Mario R. Nacinovich, Jr., MSc Guest: Kelly Cawcutt, MD If you’re looking to adopt a patient-centered approach into your own practice, tune in to hear Dr. Kelly Cawcutt, an infectious disease and critical care physician at the University of Nebraska Medical Center, break down her team’s approach with Mario Nacinovich.

Host: Mario R. Nacinovich, Jr., MSc Guest: Kelly Cawcutt, MD If you’re looking to adopt a patient-centered approach into your own practice, tune in to hear Dr. Kelly Cawcutt, an infectious disease and critical care physician at the University of Nebraska Medical Center, break down her team’s approach with Mario Nacinovich.

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Spergel, MD, PhD Get a bird’s-eye view of how oral immunotherapy (OIT) is developing in different countries with Dr. Mario Nacinovich and Dr. Jonathan Spergel, who also discusses the reasoning behind this strategy and when we should use this treatment option for our patients with food allergies.

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Spergel, MD, PhD Get a bird’s-eye view of how oral immunotherapy (OIT) is developing in different countries with Dr. Mario Nacinovich and Dr. Jonathan Spergel, who also discusses the reasoning behind this strategy and when we should use this treatment option for our patients with food allergies.

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Spergel, MD, PhD Get a bird’s-eye view of how oral immunotherapy (OIT) is developing in different countries with Dr. Mario Nacinovich and Dr. Jonathan Spergel, who also discusses the reasoning behind this strategy and when we should use this treatment option for our patients with food allergies.

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Spergel, MD, PhD Get a bird’s-eye view of how oral immunotherapy (OIT) is developing in different countries with Dr. Mario Nacinovich and Dr. Jonathan Spergel, who also discusses the reasoning behind this strategy and when we should use this treatment option for our patients with food allergies.

Host: Mario R. Nacinovich, Jr., MSc Guest: Savak Teymoorian, MD, MBA 15 years ago, we managed our glaucoma patients by giving them some eyedrops and, in severe cases, performing surgery. But now, we have to think about how we can intervene before the damage occurs, as Mario Nacinovich and Dr. Savak Teymoorian explain.

Host: Mario R. Nacinovich, Jr., MSc Guest: Kara Rood, MD A recent study following 346 pregnant patients found that 63 percent of the women were admitted into the hospital for uncertain diagnosis or delivery—all because preeclampsia has many of the same symptoms of other diseases. The good news, however, is that there’s a new test currently underway that could make the diagnosis and treatment of preeclampsia easier in order to prevent potentially dangerous outcomes for the mother and baby, as OB/GYN Dr. Kara Rood explains.

Host: Mario R. Nacinovich, Jr., MSc Guest: Kara Rood, MD A recent study following 346 pregnant patients found that 63 percent of the women were admitted into the hospital for uncertain diagnosis or delivery—all because preeclampsia has many of the same symptoms of other diseases. The good news, however, is that there’s a new test currently underway that could make the diagnosis and treatment of preeclampsia easier in order to prevent potentially dangerous outcomes for the mother and baby, as OB/GYN Dr. Kara Rood explains.

Host: Mario R. Nacinovich, Jr., MSc Guest: Kara Rood, MD A recent study following 346 pregnant patients found that 63 percent of the women were admitted into the hospital for uncertain diagnosis or delivery—all because preeclampsia has many of the same symptoms of other diseases. The good news, however, is that there’s a new test currently underway that could make the diagnosis and treatment of preeclampsia easier in order to prevent potentially dangerous outcomes for the mother and baby, as OB/GYN Dr. Kara Rood explains.

Host: Mario R. Nacinovich, Jr., MSc Guest: Kara Rood, MD A recent study following 346 pregnant patients found that 63 percent of the women were admitted into the hospital for uncertain diagnosis or delivery—all because preeclampsia has many of the same symptoms of other diseases. The good news, however, is that there’s a new test currently underway that could make the diagnosis and treatment of preeclampsia easier in order to prevent potentially dangerous outcomes for the mother and baby, as OB/GYN Dr. Kara Rood explains.

Host: Mario R. Nacinovich, Jr., MSc Guest: Raj Mehra, PH.D. Seelos Therapeutics is leading the charge against central nervous system (CNS) disorders by advancing late-stage therapeutic candidates with proven mechanisms of action for patients with suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). And Mario Nacinovich welcomes Dr. Raj Mehra, Chairman, Founder, and CEO of Seelos Therapeutics, to hear all about it.

Host: Mario R. Nacinovich, Jr., MSc Guest: Zachary Palace, MD, CMD, FACP Guest: Robert Accetta At the American Society of Consultant Pharmacists Annual Meeting, Mario Nacinovich caught up with Dr. Zachary Palace and Robert Accetta. As they dispel current misconceptions, Dr. Palace and Mr. Accetta shed light on medical cannabis and the impact they’ve seen it have in practice.

Host: Mario R. Nacinovich, Jr., MSc Guest: Kalin Clifford, PharmD Focusing on hospital-acquired and ventilator-associated pneumonia in older adults, Mario Nacinovich is joined by Dr. Kalin Clifford at the American Society of Consultant Pharmacists Annual Meeting. Together they dive deep into these two types of pneumonia to reveal new guidelines and the latest treatment options.